Linked Data API

Show Search Form

Search Results

1041209
registered interest false more like this
date less than 2019-01-14more like thismore than 2019-01-14
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading University Hospitals Bristol NHS Foundation Trust: Liothyronine more like this
house id 2 remove filter
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government what action they plan to take to lift the ban on the prescription of liothyronine (T3) by University Hospital Bristol in contradiction of the advice given by NHS England. more like this
tabling member printed
Lord Hunt of Kings Heath more like this
uin HL12791 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-01-22more like thismore than 2019-01-22
answer text <p>NHS England is working closely with clinical commissioning groups (CCGs) on the prescribing of liothyronine to support them with the implementation of guidance for CCGs on items which should not be routinely prescribed in primary care. The Department has not had specific discussions with NHS England or made an assessment on these issues.</p><p>CCGs are expected to have regard to national guidance, and are responsible for developing their own local approaches to its implementation taking into account local priorities and needs. CCGs set the policy which governs what hospitals and trusts implement, therefore the prescription of liothyronine at University Hospital Bristol and Musgrove Park Hospital in Taunton is a matter for those CCGs.</p><p>This guidance for CCGs on items which should not be routinely prescribed in primary care includes recommendations on the use of liothyronine in line with the British Thyroid Association, who advise that a small proportion of patients treated with levothyroxine continue to suffer with symptoms despite adequate biochemical correction. In these circumstances,</p><p>where levothyroxine has failed and in line with this guidance, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of at least three months duration of the drug.</p><p>Further guidance on the prescribing of liothyronine has been published by the Regional Medicines Optimisation Committee. The aim of the guidance is to make best practice on the prescribing of liothyronine clearer. A copy of <em>Guidance – Prescribing of Liothyronine</em> is attached.</p>
answering member printed Baroness Manzoor more like this
grouped question UIN
HL12792 more like this
HL12793 more like this
HL12794 more like this
question first answered
less than 2019-01-22T16:17:24.337Zmore like thismore than 2019-01-22T16:17:24.337Z
answering member
4289
label Biography information for Baroness Manzoor more like this
attachment
1
file name RMOC-Liothyronine-Guidance-v2.0-final-1.pdf more like this
title RMOC liothyronine guidance more like this
tabling member
2024
label Biography information for Lord Hunt of Kings Heath more like this